---
title: "Mortality and Predictors Among People Living with HIV Newly Enrolled in Care at Bamenda Regional H"
id: "medrxiv-11-mortality-and-associated-factors-among-people-living-with-hiv-newly-initiated"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-11-mortality-and-associated-factors-among-people-living-with-hiv-newly-initiated"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.17.26358304v1?rss=1"
published_at: "2026-07-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Mortality and Predictors Among People Living with HIV Newly Enrolled in Care at Bamenda Regional H
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-11-mortality-and-associated-factors-among-people-living-with-hiv-newly-initiated
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.17.26358304v1?rss=1)
- **Published At:** 2026-07-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This retrospective cohort assessed **mortality** and associated factors among 331 people living with HIV (PLHIV) newly initiated on antiretroviral therapy (ART) at Bamenda Regional Hospital between January 2021 and December 2023. - Data were abstracted from medical records; analysis used R v4.3.1 and a multivariable Cox regression to identify mortality predictors while adjusting for confounders. - Participants had a mean age of 41.6 ± 11.7 years; 57.7% were female. - Opportunistic diseases were recorded in 19.0% of participants, with **tuberculosis** the most common (8.2%). - Key comorbidities included **hypertension** (8.8%), **diabetes** (3.9%) and **hepatitis B** (3.0%). - Laboratory results showed elevated liver enzymes (ALAT/ASAT mean 41.7 ± 23.6 U/L) and raised blood glucose (mean 144.4 ± 7.4 mg/dL); creatinine and lymphocyte counts were near normal. - Observed cumulative mortality over three years was 7.6% (about 2.5% per year). - Independent predictors of mortality included **male sex** (AHR=7.83), presence of **opportunistic diseases** (AHR=5.66), presence of **comorbidities** (AHR=6.04), abnormal **ALAT/ASAT** (p=0.005), and **WHO clinical stage III** (AHR 1.1). - Body mass index (BMI) and ART adherence were not statistically significant predictors in the multivariable model. - Authors conclude that advanced disease, opportunistic infections, comorbid conditions and abnormal laboratory indicators were associated with higher mortality and recommend strengthening early diagnosis, opportunistic infection management and clinical and laboratory monitoring to reduce mortality.
## Clinical Analysis & Structured Key Points
Skip to main content HOMESUBMITFAQBLOGALERTS / RSSRESOURCESABOUT Search for this keyword Advanced Search Follow this preprint Mortality and associated factors among people living with HIV newly initiated into care at Bamenda Regional Hospital: A Retrospective Cohort Study View ORCID Profile Faustus Ajamah, Jude Tsafack Zefack, Lucas Tanlaka Mengnjo, View ORCID Profile Onesimus Yongwa, Michael Agbor Ashu, Selouis Fuanyi Nkengfua, Huldah Mbinyui, Alice Ketchaji doi: https://doi.org/10.64898/2026.07.17.26358304 This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. AbstractInfo/HistoryMetrics Preview PDF Abstract Introduction Globally and in Africa, HIV mortality is reported to have decreased over the years. Cameroon's national mortality rate was 1.7% in 2023, and there exist regional disparities and underreporting. We assessed the mortality and associated factors among People Living with HIV(PLHIV) initiated into HIV care from January 2021 to December 2023 at the Bamenda regional hospital (BRH) Methods A retrospective cohort study was conducted from June 2024 to December 2024 at the BRH. Using a non-probabilistic consecutive sampling technique, 331 newly initiated participants on ART were included. Data was collected from medical records using a questionnaire and analyzed using R software version 4.3.1. A multivariable Cox regression model included variables that showed statistical significance and assessed their relationship with mortality while adjusting for potential confounders. Significant predictors of mortality were identified. Results The mean age of participants was 41.6 ± 11.7 years, and females constituted 57.7%. Opportunistic diseases were present in 19.0% of cases, with tuberculosis (8.2%) being the most common. Key comorbidities included hypertension (8.8%), diabetes (3.9%), and hepatitis B (3.0%). Blood tests showed elevated liver enzymes (ALAT/ASAT: 41.7±23.6 U/L) and high blood sugar (144.4±7.4 mg/dL). In contrast, kidney function (Creatinine: 0.9±0.2 mg/dL) and immune cell counts (Lymphocytes: 1.8±0.7 x103/μL) appeared normal overall. A cumulative mortality rate of 7.6% over three years (approximately 2.5% per year) was observed. Male sex (AHR=7.83, 95% CI:1.44-42.5, p=0.017), opportunistic diseases (AHR=5.66, 95% CI:1.71-18.7, p=0.004), comorbidities (AHR=6.04, 95% CI:2.02-18.1, p=0.001), Abnormal ALAT/ASAT (p=0.005), and WHO clinical stage III (AHR: 1.1, 95%CI: 1.01 -1.5, p < 0.001), were identified as predictors of mortality. Whereas, BMI and ART adherence showed no significance. Conclusion Mortality among PLHIV in this study was associated with advanced disease, opportunistic diseases, commorbidities and abnormal laboratory findings. Strengthening early diagnosis, management of opportunistic infections, and monitoring of clinical and laboratory indicators may help reduce mortality in this population. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical approval was obtained from the Institutional Review Board of the Catholic University of Central Africa (Ref: 2024/02082/CEIRSH/ESS/MSP) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. bioRxiv and medRxiv thank the following for their generous financial support: The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. Donate to openRxiv Back to top Previous Next Posted July 20, 2026. Download PDF Print/Save Options Author Declarations Data/Code Email Share Citation Tools Get QR code Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos Subject Areas All Articles Addiction Medicine Allergy and Immunology Anesthesia Cardiovascular Medicine Dentistry and Oral Medicine Dermatology Emergency Medicine Endocrinology (including Diabetes Mellitus and Metabolic Disease) Epidemiology Forensic Medicine Gastroenterology Genetic and Genomic Medicine Geriatric Medicine Health Economics Health Informatics Health Policy Health Systems and Quality Improvement Hematology HIV/AIDS Infectious Diseases (except HIV/AIDS) Intensive Care and Critical Care Medicine Medical Education Medical Ethics Nephrology Neurology Nursing Nutrition Obstetrics and Gynecology Occupational and Environmental Health Oncology Ophthalmology Orthopedics Otolaryngology Pain Medicine Palliative Medicine Pathology Pediatrics Pharmacology and Therapeutics Primary Care Research Psychiatry and Clinical Psychology Public and Global Health Radiology and Imaging Rehabilitation Medicine and Physical Therapy Respiratory Medicine Rheumatology Sexual and Reproductive Health Sports Medicine Surgery Toxicology Transplantation Urology Evaluation/discussion of this paper x 0 0 0 0 0 0 We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. Continue Find out more
## Related Clinical Research

- [Determinants of Favorable MDR-TB Treatment Outcomes in Zambia, 2018–2022](https://medichelpline.com/clinical-feed/plos-one-16-determinants-of-favorable-treatment-outcomes-in-multidrug-resistant.md)
- [Predictors of Healthcare Costs for Commercially Insured Adults with Tuberculosis in the US (2013–2](https://medichelpline.com/clinical-feed/medrxiv-0-predictors-of-healthcare-costs-among-commercially-insured-persons-with.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [HBsAg clearance and occult HBV mutation in HIV/HBV-coinfected patients on ART](https://medichelpline.com/clinical-feed/medrxiv-7-hepatitis-b-surface-antigen-clearance-in-hiv-hbv-coinfected-patients-associated.md)
- [Market landscape of penicillin for syphilis and rheumatic heart disease in WHO South‑East Asia Reg](https://medichelpline.com/clinical-feed/pubmed-42676699.md) (DOI: 10.2471/BLT.25.295053)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.